72744-56-0

Basic information

• Product Name: 5-BROMO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID
• Synonyms: 5-BROMO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID;5-BROMOBENZO[1,3]DIOXOLE-4-CARBOXYLIC ACID;5-Brombenzo[1,3]dioxol-4-carbonsure;5-bromobenzo[d][1,3]dioxole-4-carboxylic acid
• CAS NO: 72744-56-0
• Molecular Formula: C₈H₅BrO₄
• Molecular Weight: 245.0269
• Product Categories: C8;Carbonyl Compounds;Carboxylic Acids
• Mol File: 72744-56-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 169-173 °C
• Boiling Point: 353.188°C at 760 mmHg
• Flash Point: 167.403°C
• Appearance: /
• Density: 1.895g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.648
• PKA: 2.62±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID(72744-56-0)
• EPA Substance Registry System: 5-BROMO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID(72744-56-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 72744-56-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H5BrO4/c9-4-1-2-5-7(13-3-12-5)6(4)8(10)11/h1-2H,3H2,(H,10,11)

Upstream product

• 83983-71-5 6-bromo-2,3-dihydroxybenzaldehyde 
• 20035-45-4 6-bromo-3-ethoxy-2-hydroxybenzaldehyde 
• 492-88-6 3-ethoxysalicylaldehyde 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 124-38-9 carbon dioxide 
• 72744-54-8 5-bromo-benzo[1,3]dioxole-4-carbaldehyde 

Downstream Products

• 401811-77-6 N-(5-bromo-1,3-benzodioxol-4-yl)carbamic acid 1,1-dimethylethyl ester 
• 401811-78-7 5-bromobenzo[d][1,3]dioxol-4-amine 
• 98260-77-6 2,3,7,8-bismethylenedioxy-6,11-dimethoxy-5-methyl-5,6-dihydrobenzophenanthridine 
• 1337985-49-5 (+)-12-(3-chlorobenzoyloxy)-10b,11-dihydroxy-5-methyl-2,3:7,8-bis(methylenedioxy)-4b,5,6,10b,11,12-hexahydrobenzo[c]phenanthridin-6(5H)-one 
• 1337985-48-4 (+)-12-(3-chlorobenzoyloxy)-11-hydroxy-5-methyl-2,3:7,8-bis(methylenedioxy)-10b-triethylsilyloxy-4b,5,6,10b,11,12-hexahydrobenzo[c]phenanthridin-6(5H)-one 
• 88200-01-5 (-)-11-hydroxy-5-methyl-2,3:7,8-bis(methylenedioxy)-4b,5,6,10b,11,12-hexahydrobenzo[c]phenanthridine 
• 1235871-36-9 C₂₆H₂₀BrNO₅ 
• 1235871-31-4 N-(5-([1,1'-biphenyl]-4-yl)-6,7-dimethoxynaphthalen-1-yl)-5-bromobenzo[d][1,3]dioxole-4-carboxamide 
• 1235871-73-4 N-(4-(biphenyl-4-yl)-6,7-dimethoxynaphthalen-1-yl)-5-bromobenzo[1,3]dioxole-4-carboxamide 
• 1235871-06-3 C₂₇H₂₂NO₄⁽¹⁺⁾*Cl^(1-) 
• 1235871-05-2 8-biphenyl-4-yl-9,10-dimethoxy-12-methyl-1,3-dioxa-12-azoniacyclopenta[a]chrysene chloride 
• 1235871-14-3 C₃₃H₂₆NO₄⁽¹⁺⁾*Cl^(1-) 
• 1235871-37-0 C₂₇H₂₂BrNO₅ 

Relevant articles and documents

Enantioselective Divergent Syntheses of (+)-Bulleyanaline and Related Isoquinoline Alkaloids from the Genus Corydalis

The isoquinoline alkaloids isolated from the genus Corydalis possess potent and diverse biological activities. Herein, a concise, divergent, and enantioselective route to access these natural products is disclosed. Key transformations of our approach incl

Structure-activity relationship studies of phenanthridine-based Bcl-X L inhibitors

Despite their structural similarities, the natural products chelerythrine (5) and sanguinarine (6) target different binding sites on the pro-survival Bcl-XL protein. This paper details the synthesis of phenanthridine-based analogues of the natu

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.